Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on tumor recurrence and hard-to-treat established tumors, today announced that on Monday, 14 March it will host an investor event providing the opportunity to meet with Immunicum’s leadership team. The event will take place at 6:00pm CET at the Clarion Hotel Post in Gothenburg, Sweden.
The following leadership team members will be present at the event:
- Erik Manting, Ph.D., Chief Executive Officer
- Lotta Ferm, Chief Financial Officer
- Jeroen Rovers, M.D., Ph.D., Chief Medical Officer
The meeting will be held as a local event only.
Date: Monday, 14 March 2022
Venue: Clarion Hotel Post, Drottningtorget 10, Gothenburg
Time: 18.00 - 19.30, registration in-person attendance starting at 17.30
Since capacity is limited, please register your interest to participate in the event by email to ir@immunicum.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@immunicum.com
INVESTOR RELATIONS
Brendan Payne
Stern Investor Relations
Telephone: +1 212-698-8695
E-mail: brendan.payne@sternir.com
MEDIA RELATIONS
Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu
ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment
